Success Metrics

Active Trials

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Ph early_phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (33.3%)

Phase 11 (33.3%)

Phase 21 (33.3%)

Trials by Status

not_yet_recruiting267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

not_yet_recruitingphase_2

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

NCT07802652

recruitingphase_1

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

NCT06819735

not_yet_recruitingearly_phase_1

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

NCT07213882

Clinical Trials (3)

Showing 3 of 3 trials

NCT07802652Phase 2

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

Not Yet Recruiting

NCT06819735Phase 1

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Recruiting

NCT07213882Early Phase 1

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3